Vertex Pharmaceuticals EVP Sells Nearly $440K in Shares

Joy Liu, an executive vice president at the biotech company, disposed of nearly 1,000 shares in a pre-arranged transaction.

Apr. 4, 2026 at 10:28am

Got story updates? Submit your updates here. ›

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Joy Liu sold 978 shares of the company's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $449.17, for a total value of $439,288.26. Following the sale, Liu owned 21,833 shares in the company, valued at $9,806,728.61.

Why it matters

Insider trading activity can provide insights into a company's performance and the views of its leadership. While this sale represents a relatively small portion of Liu's overall holdings, it may signal that Vertex executives see the stock as overvalued at current levels.

The details

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to schedule stock sales in advance and avoid accusations of trading on material non-public information. Vertex Pharmaceuticals is a Boston-based biotech firm focused on developing treatments for serious diseases, particularly cystic fibrosis.

  • The stock sale occurred on Wednesday, April 1, 2026.

The players

Joy Liu

An executive vice president at Vertex Pharmaceuticals.

Vertex Pharmaceuticals

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

What’s next

Investors will likely continue to monitor Vertex Pharmaceuticals' stock performance and any further insider trading activity as the company progresses with its drug development pipeline.

The takeaway

This insider sale, while relatively small, could signal that Vertex's leadership believes the stock is overvalued at current levels, even as the company continues to make advancements in its cystic fibrosis treatments and other areas.